Title:
DOUBLE-STRANDED RIBONUCLEIC ACID FOR INHIBITING HMGB1 GENE EXPRESSION, AND MODIFIER, CONJUGATE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/061202
Kind Code:
A1
Abstract:
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibiting HMGB1 gene expression, a double-stranded RNA modifier, a double-stranded RNA conjugate, a pharmaceutical composition, a use, and a method for inhibiting intracellular HMGB1 gene expression. The double-stranded RNA provided by the present disclosure can be combined in cells to form an RNA-induced silencing complex (RISC), cuts mRNA transcribed by an HMGB1 gene, efficiently and specifically inhibits the expression of the HMGB1 gene, is used for treating HMGB1 gene-mediated diseases, and has important application prospects in clinical disease treatment.
Inventors:
WANG YAN (CN)
HUANG HE (CN)
WANG SHUCHENG (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
HUANG HE (CN)
WANG SHUCHENG (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
Application Number:
PCT/CN2023/119654
Publication Date:
March 28, 2024
Filing Date:
September 19, 2023
Export Citation:
Assignee:
BEIJING WINSUNNY PHARMACEUTICAL CO LTD (CN)
International Classes:
C12N15/113; A61K31/713; A61P7/00; A61P9/00; A61P9/10; A61P11/06; A61P13/00; A61P13/12; A61P17/00; A61P19/02; A61P21/04; A61P25/00; A61P25/28; A61P27/02; A61P29/00; A61P37/02; A61P37/06
Domestic Patent References:
| WO2020139764A1 | 2020-07-02 |
Foreign References:
| CN111050776A | 2020-04-21 | |||
| CN111727252A | 2020-09-29 |
Other References:
LI HAI-TAO; CAI FEI; HU GUO-FU; TENG YUN-FEI: "miRNA-218-5p Inhibits Inflammatory Response via HMGB1 Signaling Pathway in RAW264.7 Cell-derived Foam Cells", CHINESE JOURNAL OF PATHOPHYSIOLOGY, ZHONGGUO BINGLI SHENGLI XUEHUI, BEIJING, CN, vol. 38, no. 8, 25 August 2022 (2022-08-25), CN , pages 1370 - 1375, XP009553414, ISSN: 1000-4718
JIANG SHUANG, CHEN XIAOLONG: "HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo", DRUG DESIGN, DEVELOPMENT AND THERAPY, DOVE MEDICAL PRESS LTD., UNITED KINGDOM, vol. 11, 15 March 2017 (2017-03-15), United Kingdom , pages 783 - 795, XP093151069, ISSN: 1177-8881, DOI: 10.2147/DDDT.S129913
JIANG SHUANG, CHEN XIAOLONG: "HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo", DRUG DESIGN, DEVELOPMENT AND THERAPY, DOVE MEDICAL PRESS LTD., UNITED KINGDOM, vol. 11, 15 March 2017 (2017-03-15), United Kingdom , pages 783 - 795, XP093151069, ISSN: 1177-8881, DOI: 10.2147/DDDT.S129913
Attorney, Agent or Firm:
LINDA LIU & PARTNERS (CN)
Download PDF:
Previous Patent: DISPLAY METHOD AND APPARATUS, ELECTRONIC DEVICE, AND COMPUTER READABLE MEDIUM
Next Patent: PHARMACEUTICAL COMPOSITION AND USE THEREOF
Next Patent: PHARMACEUTICAL COMPOSITION AND USE THEREOF